Global epidemiology of gout: prevalence, incidence and risk factors

被引:1210
作者
Kuo, Chang-Fu [1 ]
Grainge, Matthew J. [2 ]
Zhang, Weiya [3 ]
Doherty, Michael [3 ]
机构
[1] Chang Gung Mem Hosp, Div Rheumatol Allergy & Immunol, Taoyuan 333, Taiwan
[2] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England
[3] Univ Nottingham, Sch Med, Div Rheumatol Orthopaed & Dermatol, Nottingham NG5 1PB, England
关键词
SERUM URIC-ACID; WHO-ILAR COPCORD; MENDELIAN RANDOMIZATION ANALYSIS; INFLAMMATORY RHEUMATIC DISEASES; ENVIRONMENTAL LEAD-EXPOSURE; POPULATION-BASED COHORT; CORONARY-HEART-DISEASE; PURINE-RICH FOODS; ATHEROSCLEROSIS RISK; MUSCULOSKELETAL DISEASES;
D O I
10.1038/nrrheum.2015.91
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Gout is a crystal-deposition disease that results from chronic elevation of uric acid levels above the saturation point for monosodium urate (MSU) crystal formation. Initial presentation is mainly severely painful episodes of peripheral joint synovitis (acute self-limiting 'attacks') but joint damage and deformity, chronic usage-related pain and subcutaneous tophus deposition can eventually develop. The global burden of gout is substantial and seems to be increasing in many parts of the world over the past 50 years. However, methodological differences impair the comparison of gout epidemiology between countries. In this comprehensive Review, data from epidemiological studies from diverse regions of the world are synthesized to depict the geographic variation in gout prevalence and incidence. Key advances in the understanding of factors associated with increased risk of gout are also summarized. The collected data indicate that the distribution of gout is uneven across the globe, with prevalence being highest in Pacific countries. Developed countries tend to have a higher burden of gout than developing countries, and seem to have increasing prevalence and incidence of the disease. Some ethnic groups are particularly susceptible to gout, supporting the importance of genetic predisposition. Socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and/or facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.
引用
收藏
页码:649 / 662
页数:14
相关论文
共 195 条
[1]
GOUT AND CORONARY HEART-DISEASE - THE FRAMINGHAM-STUDY [J].
ABBOTT, RD ;
BRAND, FN ;
KANNEL, WB ;
CASTELLI, WP .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1988, 41 (03) :237-242
[2]
Hyperuricemia in Saudi Arabia [J].
Al-Arfaj, AS .
RHEUMATOLOGY INTERNATIONAL, 2001, 20 (02) :61-64
[3]
DEVELOPMENT OF ACUTE GOUT SECONDARY TO PYRAZINAMIDE IN A PATIENT WITHOUT A PRIOR HISTORY OF GOUT [J].
AMODIO, MI ;
BENGUALID, V ;
LOWY, FD .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1990, 24 (11) :1115-1116
[4]
The prevalence of rheumatic diseases in central Greece: a population survey [J].
Anagnostopoulos, Ioannis ;
Zinzaras, Elias ;
Alexiou, Ioannis ;
Papathanasiou, Aphrodite A. ;
Davas, Evangelos ;
Koutroumpas, Athanasios ;
Barouta, Georgia ;
Sakkas, Lazaros I. .
BMC MUSCULOSKELETAL DISORDERS, 2010, 11
[5]
Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005 [J].
Annemans, L. ;
Spaepen, E. ;
Gaskin, M. ;
Bonnemaire, M. ;
Malier, V. ;
Gilbert, T. ;
Nuki, G. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) :960-966
[6]
[Anonymous], CLIN RHEUMATOL
[7]
Arromdee E, 2002, J RHEUMATOL, V29, P2403
[8]
Australian Bureau of Statistics, 1996, NAT HLTH SURV SUMM R
[9]
Badley E., 2003, ARTHRITIS CANADA ONG
[10]
BALL G V, 1971, Bulletin of the History of Medicine, V45, P401